These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

747 related items for PubMed ID: 17484865

  • 1. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
    Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group.
    Gastroenterology; 2007 May; 132(5):1672-83. PubMed ID: 17484865
    [Abstract] [Full Text] [Related]

  • 2. Natalizumab for active Crohn's disease.
    Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, Zádorová Z, Palmer T, Donoghue S, Natalizumab Pan-European Study Group.
    N Engl J Med; 2003 Jan 02; 348(1):24-32. PubMed ID: 12510039
    [Abstract] [Full Text] [Related]

  • 3. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.
    Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R, REACH Study Group.
    Gastroenterology; 2007 Mar 02; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398
    [Abstract] [Full Text] [Related]

  • 4. Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease.
    Hommes DW, Mikhajlova TL, Stoinov S, Stimac D, Vucelic B, Lonovics J, Zákuciová M, D'Haens G, Van Assche G, Ba S, Lee S, Pearce T.
    Gut; 2006 Aug 02; 55(8):1131-7. PubMed ID: 16507585
    [Abstract] [Full Text] [Related]

  • 5. Anti-interleukin-12 antibody for active Crohn's disease.
    Mannon PJ, Fuss IJ, Mayer L, Elson CO, Sandborn WJ, Present D, Dolin B, Goodman N, Groden C, Hornung RL, Quezado M, Yang Z, Neurath MF, Salfeld J, Veldman GM, Schwertschlag U, Strober W, Anti-IL-12 Crohn's Disease Study Group.
    N Engl J Med; 2004 Nov 11; 351(20):2069-79. PubMed ID: 15537905
    [Abstract] [Full Text] [Related]

  • 6. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.
    Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ.
    N Engl J Med; 1997 Oct 09; 337(15):1029-35. PubMed ID: 9321530
    [Abstract] [Full Text] [Related]

  • 7. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
    Thia KT, Sandborn WJ, Lewis JD, Loftus EV, Feagan BG, Steinhart AH, Hanauer SB, Persson T, Sands BE.
    Am J Gastroenterol; 2008 Dec 09; 103(12):3123-31. PubMed ID: 18786111
    [Abstract] [Full Text] [Related]

  • 8. Health-related quality-of-life evaluation of crohn disease patients after receiving natalizumab therapy.
    Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S.
    Gastroenterol Nurs; 2009 Dec 09; 32(5):327-39. PubMed ID: 19820441
    [Abstract] [Full Text] [Related]

  • 9. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W, Hommes DW, Van Assche G, Colombel JF, Gendre JP, Oldenburg B, Teml A, Geboes K, Ding H, Zhang L, Tang M, Cheng M, van Deventer SJ, Rutgeerts P, Pearce T.
    Gut; 2006 Aug 09; 55(8):1138-44. PubMed ID: 16492717
    [Abstract] [Full Text] [Related]

  • 10. Natalizumab induction and maintenance therapy for Crohn's disease.
    Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P, International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group, Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group.
    N Engl J Med; 2005 Nov 03; 353(18):1912-25. PubMed ID: 16267322
    [Abstract] [Full Text] [Related]

  • 11. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease.
    Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S.
    Dig Liver Dis; 2004 May 03; 36(5):342-7. PubMed ID: 15191204
    [Abstract] [Full Text] [Related]

  • 12. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease.
    Feagan BG, Sandborn WJ, Hass S, Niecko T, White J.
    Am J Gastroenterol; 2007 Dec 03; 102(12):2737-46. PubMed ID: 18042106
    [Abstract] [Full Text] [Related]

  • 13. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group.
    Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T.
    N Engl J Med; 1994 Sep 29; 331(13):836-41. PubMed ID: 8078529
    [Abstract] [Full Text] [Related]

  • 14. Sargramostim for active Crohn's disease.
    Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ, Sargramostim in Crohn's Disease Study Group.
    N Engl J Med; 2005 May 26; 352(21):2193-201. PubMed ID: 15917384
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab therapy for moderate to severe Crohn disease in adolescents.
    Hyams JS, Wilson DC, Thomas A, Heuschkel R, Mitton S, Mitchell B, Daniels R, Libonati MA, Zanker S, Kugathasan S, International Natalizumab CD305 Trial Group.
    J Pediatr Gastroenterol Nutr; 2007 Feb 26; 44(2):185-91. PubMed ID: 17255829
    [Abstract] [Full Text] [Related]

  • 16. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ, PRECISE 2 Study Investigators.
    N Engl J Med; 2007 Jul 19; 357(3):239-50. PubMed ID: 17634459
    [Abstract] [Full Text] [Related]

  • 17. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators.
    Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Gillies R, Hopkins M.
    N Engl J Med; 1995 Feb 02; 332(5):292-7. PubMed ID: 7816064
    [Abstract] [Full Text] [Related]

  • 18. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF, Fedorak RN, Feagan B, Fredlund P, Schmitt R, Ni P, Humphries TJ.
    Gut; 2009 Oct 02; 58(10):1354-62. PubMed ID: 19505878
    [Abstract] [Full Text] [Related]

  • 19. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease.
    Dotan I, Rachmilewitz D, Schreiber S, Eliakim R, van der Woude CJ, Kornbluth A, Buchman AL, Bar-Meir S, Bokemeyer B, Goldin E, Maaser C, Mahadevan U, Seidler U, Hoffman JC, Homoky D, Plasse T, Powers B, Rutgeerts P, Hommes D, Semapimod-CD04/CD05 Investigators.
    Gut; 2010 Jun 02; 59(6):760-6. PubMed ID: 20551461
    [Abstract] [Full Text] [Related]

  • 20. Infliximab for the treatment of fistulas in patients with Crohn's disease.
    Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ.
    N Engl J Med; 1999 May 06; 340(18):1398-405. PubMed ID: 10228190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 38.